Democratic U.S. Senate aides will meet with executives from Novo Nordisk A/S (NYSE:NVO) on Tuesday to discuss the ramifications of the company’s decision to cease selling its long-acting insulin Levemir in the U.S. by the end of 2024. Senators Jeanne Shaheen, Raphael Warnock, and Elizabeth Warren had previously expressed concerns in an April letter regarding the announcement to discontinue Levemir. Also Read: Novo Nordisk’s Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review. In November last year, Novo Nordisk announced that it would discontinue the long-acting insulin Levemir in the U.S. due to manufacturing constraints, reduced patient access, and the availability of alternative options.  Novo Nordisk maintains that patients have ample ...